News
Wyoming may see its first commercial nuclear power plant a few months sooner than anticipated, but still sometime in 2030, ...
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback